Metabolomic Insights into Lysosomal Storage Diseases: An Untargeted View

Area of Science:

• Biochemistry
• Genetics
• Metabolomics

Background:

• Lysosomal Storage Diseases (LSDs) encompass approximately 70 inherited metabolic disorders, often autosomal recessive, caused by enzyme deficiencies leading to substrate accumulation.
• These rare diseases collectively affect 1 in 5000 births, presenting heterogeneously across multiple organ systems, typically in childhood but with adult-onset forms.
• Current diagnostic methods are insufficient for presymptomatic detection, necessitating advanced approaches.

Purpose of the Study:

• To review Lysosomal Storage Diseases (LSDs) and highlight the role of untargeted metabolomics.
• To explore how metabolomics aids in identifying novel diagnostic and prognostic biomarkers.
• To uncover previously unrecognized pathogenic mechanisms for therapeutic innovation.

Main Methods:

• Review of existing literature on Lysosomal Storage Diseases (LSDs).
• Focus on studies utilizing untargeted metabolomics.
• Analysis of identified biomarkers and pathogenic pathways.

Main Results:

• Untargeted metabolomics is a potent strategy for investigating LSD pathogenesis.
• Metabolomics facilitates the discovery of novel biomarkers for diagnostic and prognostic use.
• This approach reveals previously unknown disease mechanisms.

Conclusions:

• Untargeted metabolomics is crucial for advancing the understanding and management of LSDs.
• Continued research in metabolomics promises improved diagnostic accuracy and novel therapeutic targets.
• There is a need for more sensitive and specific diagnostic tools for LSDs.